Skip to main content
Top
Published in: Diabetologia 11/2003

01-11-2003 | Rapid Communication

Globular adiponectin upregulates nitric oxide production in vascular endothelial cells

Authors: Y. Hattori, MD, M. Suzuki, S. Hattori, K. Kasai

Published in: Diabetologia | Issue 11/2003

Login to get access

Abstract

Aims/hypothesis

Adiponectin, also called ACRP30, is a novel adipose tissue-specific protein that has been shown to improve insulin sensitivity and to exert anti-atherogenic effects. It is known that knockout mice lacking endothelial NO synthase (eNOS) develop hypertension, insulin resistance, hyperlipidaemia, and show augmented ischaemia-reperfusion damage. Thus, we examined whether globular adiponectin activates eNOS to produce NO.

Methods

To analyze NO production in bovine aortic endothelial cells (BAE), NOx (nitrite and nitrate) was measured in the medium with an automated NO detector/high-performance liquid chromatography system. eNOS activation was assessed by phosphorylation of the enzyme and its activity was evaluated by citrulline synthesis in human umbilical vein endothelial cells (HUVEC). eNOS mRNA and protein expressions in HUVEC were evaluated by Realtime PCR and Western blot analysis.

Results

Gobular adiponectin increased NO production in BAE. It also caused eNOS phosphorylation and potentiated eNOS activity in HUVEC. In addition, globular adiponectin up-regulated the eNOS gene to increase protein expression in HUVEC.

Conclusion/interpretation

Globular adiponectin increases NO production through two mechanisms, namely, by activation of eNOS enzyme activity and via an increase in eNOS expression. Activation and up-regulation of eNOS could explain some of the observed vasoprotective properties of globular adiponectin, as well as its beneficial effects on the cardiovascular system.
Literature
1.
go back to reference Tsao TS, Lodish HF, Fruebis J (2002) ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 440:213–221CrossRefPubMed Tsao TS, Lodish HF, Fruebis J (2002) ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 440:213–221CrossRefPubMed
2.
go back to reference Diez JJ, Iglesias P (2003) The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148:293–300PubMed Diez JJ, Iglesias P (2003) The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148:293–300PubMed
3.
go back to reference Maeda N, Takahashi M, Funahashi T et al. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094–2099PubMed Maeda N, Takahashi M, Funahashi T et al. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094–2099PubMed
4.
go back to reference Yamauchi T, Kamon J, Waki H et al. (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276:41245–41254PubMed Yamauchi T, Kamon J, Waki H et al. (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276:41245–41254PubMed
5.
go back to reference Fruebis J, Tsao TS, Javorschi S et al. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005–2010PubMed Fruebis J, Tsao TS, Javorschi S et al. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005–2010PubMed
6.
go back to reference Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953PubMed Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953PubMed
7.
go back to reference Yamauchi T, Kamon J, Waki H et al. (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461–2468CrossRefPubMed Yamauchi T, Kamon J, Waki H et al. (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461–2468CrossRefPubMed
8.
go back to reference Matsuda M, Shimomura I, Sata M et al. (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487–37491CrossRefPubMed Matsuda M, Shimomura I, Sata M et al. (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487–37491CrossRefPubMed
9.
go back to reference Kubota N, Terauchi Y, Yamauchi T et al. (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863–26866CrossRefPubMed Kubota N, Terauchi Y, Yamauchi T et al. (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863–26866CrossRefPubMed
10.
go back to reference Ouchi N, Kihara S, Arita Y et al. (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057–1063PubMed Ouchi N, Kihara S, Arita Y et al. (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057–1063PubMed
11.
go back to reference Ouchi N, Kihara S, Arita Y et al. (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476PubMed Ouchi N, Kihara S, Arita Y et al. (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476PubMed
12.
go back to reference Yokota T, Oritani K, Takahashi I et al. (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrohages. Blood 96:1723–1732PubMed Yokota T, Oritani K, Takahashi I et al. (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrohages. Blood 96:1723–1732PubMed
13.
go back to reference Bredt DS, Snyder SH (1989) Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA 86:9030–9033PubMed Bredt DS, Snyder SH (1989) Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA 86:9030–9033PubMed
14.
go back to reference Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER (2001) L-Ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 276:40–47CrossRefPubMed Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER (2001) L-Ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 276:40–47CrossRefPubMed
15.
go back to reference Hattori Y, Hattori S, Kasai K (2001) 4-hydroxynonenal prevents NO production in vascular smooth muscle cells by inhibiting nuclear factor-kappaB-dependent transcriptioal activation of inducible NO synthase. Arterioscler Thromb Vasc Biol 21:1179–1183PubMed Hattori Y, Hattori S, Kasai K (2001) 4-hydroxynonenal prevents NO production in vascular smooth muscle cells by inhibiting nuclear factor-kappaB-dependent transcriptioal activation of inducible NO synthase. Arterioscler Thromb Vasc Biol 21:1179–1183PubMed
16.
go back to reference Chen ZP, Mitchelhill KI, Michell BJ et al. (1999) AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 443:285–289CrossRefPubMed Chen ZP, Mitchelhill KI, Michell BJ et al. (1999) AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 443:285–289CrossRefPubMed
17.
go back to reference Chen ZP, McCoell GK, Michell BJ et al. (2000) AMPK signaling in contracting human skeletal muscle: acetyl-CoA caboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab 279:E1202–1206 Chen ZP, McCoell GK, Michell BJ et al. (2000) AMPK signaling in contracting human skeletal muscle: acetyl-CoA caboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab 279:E1202–1206
18.
go back to reference Tomas E, Tsao TS, Saha AK et al. (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309–16313CrossRefPubMed Tomas E, Tsao TS, Saha AK et al. (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309–16313CrossRefPubMed
19.
go back to reference Yamauchi T, Kamon J, Minpkoshi Y et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–95CrossRefPubMed Yamauchi T, Kamon J, Minpkoshi Y et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–95CrossRefPubMed
20.
go back to reference Yu JG, Javorschi S, Hevener AL et al. (2002) The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968–2974PubMed Yu JG, Javorschi S, Hevener AL et al. (2002) The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968–2974PubMed
21.
go back to reference Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF (2002) Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 277:29359–29362CrossRefPubMed Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF (2002) Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 277:29359–29362CrossRefPubMed
22.
go back to reference Yamauchi T, Kamon J, Ito Y et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769CrossRefPubMed Yamauchi T, Kamon J, Ito Y et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769CrossRefPubMed
23.
go back to reference Arita Y, Kihara S, Ouchi N, Takahashi M (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83PubMed Arita Y, Kihara S, Ouchi N, Takahashi M (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83PubMed
24.
go back to reference Duplain H, Burcelin R, Sartori C et al. (2001) Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 104:342–345PubMed Duplain H, Burcelin R, Sartori C et al. (2001) Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 104:342–345PubMed
25.
go back to reference Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD (2000) Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49:684–687PubMed Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD (2000) Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49:684–687PubMed
26.
go back to reference Li H, Fostermann U (2000) Nitric oxide in the pathogenesis of vascular disease. J Pathol 190:244–254PubMed Li H, Fostermann U (2000) Nitric oxide in the pathogenesis of vascular disease. J Pathol 190:244–254PubMed
Metadata
Title
Globular adiponectin upregulates nitric oxide production in vascular endothelial cells
Authors
Y. Hattori, MD
M. Suzuki
S. Hattori
K. Kasai
Publication date
01-11-2003
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 11/2003
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1224-3

Other articles of this Issue 11/2003

Diabetologia 11/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.